A city where women make on average .83 for every dollar earned by men, Boston is taking steps to close the wage gap through “100% Talent: The Boston Women’s Compact.” The compact is a voluntary pledge that more than 100 Metro Boston-based organizations have already signed, indicating their promise to close the gender wage gap in the workplace. Salary data will be collected and analyzed and companies will have access to research-driven tools and support to address pay gaps and inequities. Proudly, it’s also the first initiative of its kind in the country.
The 51st Annual DIA Meeting kicked off yesterday in Washington, DC. So far it has been a whirlwind of presenting, networking and having fun at our booth (#2026 come see us)! DIA is the perfect time to announce the latest in company news, and we have no shortage of announcements to share this year.
Are you planning attend the DIA Annual Meeting later this month in Washington, DC? For those of us working in drug research and development, it’s a great time to connect with the people and organizations working to accelerate the development of new therapies and enhance patient care.
Founded in 1983 with a $30,000 loan and two military surplus desks, BBK Worldwide has become a global, multi-million dollar corporation that is changing the face of patient recruitment for clinical R&D in the pharma and biopharma industries. Today, our founding principals, Bonnie A. Brescia and Joan F. Bachenheimer have created a global enterprise – one that that is true to their philosophies of how a business, its products, services, and culture can create new opportunities for its staff, clients and benefit consumers.
What would you do if you had access to $3 million dollars to invest in improving the clinical research field? This might be a relatively small budget by some standards, but significant enough to make a difference and BBK has some very specific plans to do just that as we continue to deliver on our value proposition, BBK Worldwide: The Patients To Find the Cure.
Considering a social media campaign for your clinical trial? While there are proven advantages to using social media as a patient recruitment tactic, additional considerations must be explored when deciding if social media fits your campaign’s needs. First, scope out your audience by evaluating the opportunity with a social media listening program. For example, how active and engaged is this study community on social media? Or, how many Facebook groups, outlets, etc. are out there for these patients to find each other? Next, evaluate the outlet – What are all my options when building a social media page? Or, what outlets can I use if I just want to advertise?
A few weeks ago, and nearly five years after its open hearing on the topic, the Food and Drug Administration (FDA) finally released its proposed guidelines for how drug and device makers should navigate social media. Much has been written on the new guidelines including a few informative posts by Ed Silverman at the Wall Street Journal. As Silverman notes, among the 50 largest drug makers, half are still not using social media to engage consumers or patients, according to a survey by the IMS Institute for Health Informatics. He also suggests that the FDA will likely use the guidances as trial-and-error blueprints themselves as they run across questions that were not answered or situations that may not have been anticipated.
Even if you were able to correlate advertising referrals to consented patients with a high degree of accuracy (and then to screen-fail and randomization) the fact of the matter is, "So what?"
Four scenarios spring to mind with regard to the quest for this correlation:
DIA 2014 50th Annual Meeting, SAN DIEGO, Calif. and BOSTON, Mass., June 17, 2014 --BBK Worldwide, a leading clinical trial marketing firm, and CROèe, the first consulting Japanese CRO specializing in patient recruitment, today announced the creation of a jointly-owned US-based company, BBK + CROèe. Collaborators since 2010, the new partners formed the entity to provide the cultural and marketing expertise necessary to engage the Japanese pharmaceutical industry and, in turn, to support global pharma in its quest for drug approvals in Japan, the second largest pharmaceutical marketplace in the world next to the US.
Topics: BBK Worldwide
New R&D Model Protects Performance in a Threatened Enrollment Landscape
DIA 2014 50th Annual Meeting, SAN DIEGO, Calif. and BOSTON, Mass., June 16, 2014--BBK Worldwide, the leader in patient recruitment, today unveiled a new specialty in clinical trial marketing: adaptive recruitment. Designed specifically to protect global enrollment integrity, within a changing or threatened landscape, adaptive recruitment helps sites and sponsors maximize tight budgets and timeframes by offering the tools and best-practices needed to ensure more informed recruitment and enrollment decisions – and the ability to seamlessly employ real-time corrections as needed. BBK Principal Matthew Stumm will discuss this new model in detail during his DIA Annual Meeting presentation, "Adopting New Strategies for the New Face of Patient Recruitment," on Tuesday, June 17 at 2:45 p.m. PST.